



smith & hopfen, p.a.
Intellectual Property Law Patents Trademarks Copyrights

January 5, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicants: Matt Ewert et al.
Serial No.: 10/604,779
Filing Date: 08/15/2003
For: Early Detection of Pathogens in Blood
Our Reference No.: 1372.49.PRC

Examiner: Unassigned
Art Unit: 1644

Dear Sir:

Enclosed please find the following:

1. Information Disclosure Statement By Applicants - 6 pages;
2. Copies of the front covers of sixty-two (62) Non-Patent Literature Documents; and
3. Self-addressed, postage prepaid post card to serve as a receipt for items 1-2.

Very respectfully,

SMITH & HOPEN

By: Anton J. Hopfen
anton.hopen@baypatents.com

AJH/sb
enclosure

CERTIFICATE OF MAILING
(37 C.F.R. 1.8)

I HEREBY CERTIFY that this correspondence is being mailed with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 5, 2004.

Date: January 5, 2004

Shelley Butz


Attorney-Client Privileged Communication

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

C m p l t if Known

Application Number 10/604,779

Filing Date 08/15/2003

First Named Inventor Matt Ewert

Group Art Unit 1644

Examiner Name Unassigned

Attorney Docket Number 1372.49.PRC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Polymerase Chain Reaction for Rapid Diagnosis of Candidemia; Bull Acad Mil Med Science; Vol. 22, No. 3; September 1998.	
	2	ARCHIBALD ET AL.; Comparison of BACTEC MYCO/F LYTIC and WAMPOLE ISOLATOR 10 (Lysis-Centrifugation)...; Journal of Clinical Micro.; pg. 2994-2997; August 2000.	
	3	BRANNON ET AL.; Clinical Comparison of Lysis-Centrifugation and Radiometric Resin Systems for Blood Culture; Journal of Clinical Microbiology; pg. 886-887; November 1986.	
	4	SIERSEMA ET AL.; Blood Culture Bottles are Superior to Lysis-Centrifugation Tubes for Bacteriological Diagnosis...; Journal of Clinical Microbiology; pg. 667-669; March 1992.	
	5	HAMILTON ET AL.; Effect of Delay in Processing on Lysis-Centrifugation Blood Culture Results from Marrow Transplant Patients; Journal of Clinical Microbiology; pg. 1588-1593; July 1989.	
	6	BERNHARDT ET AL.; Detection of Bacteria in Blood by Centrifugation and Filtration; Journal of Clinical Microbiology; pg. 422-425; March 1991.	
	7	HOFFMAN ET AL.; Bone Marrow Aspirate Culture Superior to Streptokinase Clot Culture and 8 ML 1:10 Blood-To-Broth...; American Society of Tropical Medicine & Hygiene; pg. 836-839; 1986.	
	8	AL-SOUD ET AL.; Purification and Characterization of PCR-Inhibitory Components in Blood Cells; Journal of Clinical Microbiology; pg. 485-493; February 2000.	
	9	MORATA ET AL.; Diagnostic Yield of a PCR Assay in Focal Complications of Brucellosis; Journal of Clinical Microbiology; pg. 3743-3746; October 2001.	
	10	LI ET AL.; Effects of Volume and Periodicity on Blood Cultures; Journal of Clinical Microbiology; pg. 2829-2831; November 1994.	
	11	KLEVEZAS ET AL.; Single-Step PCR for Detection of Brucella spp. from Blood and Mild of Infected Animals; Journal of Clinical Microbiology; pg. 3087-3090; December 1995.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **6**

Complete if Known

Application Number	10/604,779
Filing Date	08/15/2003
First Named Inventor	Matt Ewert
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	1372.49.PRC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	ORTUNO ET AL.; Rapid Diagnosis of Human Brucellosis by Peripheral-Blood PCR Assay; Journal of Clinical Microbiology; pg. 2927-2930; November 1997.	
	13	GSMBOA ET AL.; Detection and Identification of Mycobacteria by Amplification of RNA and DNA in Pretreated Blood and Bone...; Journal of Clinical Microbiology; pg. 2124-2128; August 1997.	
	14	MORATA ET AL.; Posttreatment Follow-Up of Brucellosis by PCR Assay; Journal of Clinical Microbiology; pg. 4163-4166; December 1999.	
	15	HAMILTON ET AL.; Effect of Delay in Processing on Lysis-Centrifugation Blood Culture Results from Marrow Transplant Patients; Journal of Clinical Microbiology; pg. 1588-1593; July 1989.	
	16	BERNHARDT ET AL.; Detection of Bacteria in Blood by Centrifugation and Filtration; Journal of Clinical Microbiology; pg. 422-425; March 1991.	
	17	HOFFMAN ET AL.; Bone Marrow Aspirate Culture Superior to Streptokinase Clot Culture and 8 ML 1:10 Blood-To-Broth...; American Society of Tropical Medicine & Hygiene; pg. 836-839; 1986.	
	18	AL-SOUD ET AL.; Purification and Characterization of PCR-Inhibitory Components in Blood Cells; Journal of Clinical Microbiology; pg. 485-493 February.	
	19	MORATA ET AL.; Diagnostic Yield of a PCR Assay in Focal Complications of Brucellosis; Journal of Clinical Microbiology; pg. 3743-3746; October 2001.	
	20	LI ET AL.; Effects of Volume and Periodicity on Blood Cultures; Journal of Microbiology; pg. 2829-2831; November 1994.	
	21	LEAL-KLEVEZAS ET AL.; Single-Step PCR for Detection of Brucella spp. from Blood and Milk of Infected Animals; Journal of Clinical Microbiology; pg. 3087-3090; December 1995.	
	22	QUEIPO-ORTUNO ET AL.; Rapid Diagnosis of Human Brucellosis by Peripheral-Blood PCR Assay; Journal of Clinical Microbiology; pg. 2927-2930; November 1997.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **6**

Complete if Known

Application Number	10/604,779
Filing Date	08/15/2003
First Named Inventor	Matt Ewert
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	1372.49.PRC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	GAMBOA ET AL.; Detection and Identification of Mycobacteria by Amplification of RNA and DNA in Pretreated Blood and Bone...; Journal of Clinical Microbiology; pg. 2124-2128; August 1997.	
	24	MORATA ET AL.; Posttreatment Follow-Up of Brucellosis by PCR Assay; Journal of Clinical Microbiology; pg. 4163-4166; December 1999.	
	25	HAMILTON ET AL.; Effect of Delay in Processing on Lysis-Centrifugation Blood Culture Results from Marrow Transplant Patients; Journal of Clinical Microbiology; pg. 1588-1593; July 1989.	
	26	CASSELS ET AL.; The Interaction of Streptokinase-Plasminogen Activator Complex, Issue-Type Plasminogen Activator, Urokinase and Their Acylated...; Journal of Biochem; pg. 395-400; 1987.	
	27	CASTELLINO; Biochemistry of Human Plasminogen; Seminars in Thrombosis & Hemostasis; vol. 10, no. 1; 1984.	
	28	MILES ET AL.; Binding and Activation of Plasminogen on the Platelet Surface; Journal of Biological Chemistry; vol. 260, no. 7; pg. 4303-4311; April 1985.	
	29	GAFFNEY ET AL.; Plasma Fibrinogen and its Fragments During Streptokinase Treatment; British Journal of Haematology; 1974.	
	30	MALIN ET AL.; Effect of Tetrahydropyrimidine Derivatives on Protein-Nucleic Acids Interaction; Journal of Biological Chemistry; vol. 274; pg. 6920-6929; March 12, 1999.	
	31	MALIN ET AL.; Induction of Synthesis of Tetrahydropyrimidine Derivatives in Steptomyces Strains and Their Effect on Escherichia Coli...; Journal of Bacteriology; pg. 385-395; January 1996.	
	32	Phospholipase A2 from Bee Venom; Methods in Enzymology, vol. 71; 1981.	
	33	NGUYEN ET AL.; Thrombolysis Using Liposomal-Encapsulated Streptokinase: An In Vitro Study; vol. 192; P.S.E.B.M.; 1989.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Completion if Known

Application Number	10/604,779
Filing Date	08/15/2003
First Named Inventor	Matt Ewert
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	1372.49.PRC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	CAO ET AL.; The Purification and Characterization of a Phospholipase A in Hamster Heart...; Journal of Biological Chemistry; vol. 262, no. 35; pg. 16927-16935; December 15, 1987.	
	35	FISHER ET AL.; Lysosomal-type PLA2 & Turnover of Alveolar DPPC; Lung Cellular & Molecular Physiology; vol. 280; pg. 74-754; April 2001.	
	36	CHEN ET AL.; 1-Cys Peroxiredoxin, a Bifunctional Enzyme with Glutathione Peroxidase and Phospholipase A2 Activities; Journal Biological Chemistry; vol. 275; pg. 28421-28427; Sept. 2000.	
	37	SHIPOLINI ET AL.; Phospholipase A from Bee Venom; Journal Biological Chemistry; pg. 459-468; 1971.	
	38	MENASHE ET AL.; Hydrolysis of Dipalmitoylphosphatidylcholine Small Unilamellar Vesicles by Porcine Pancreatic...; Journal of Biological Chemistry; vol. 261, no. 12; pg. 5328-5333; 1986.	
	39	MOLLOY ET AL.; Proteomic Analysis of the Escherichia Coli Outer Membrane; Journal of Biological Chemistry; pg. 2871-2881; 2000.	
	40	SPONER ET AL.; Electronic Properties, Hydrogen Bonding, Stacking, and Cation Binding of DNA and RNA Bases; Institute of Biophysics; August 2001.	
	41	GONZALEZ ET AL.; Mechanism of Action of Polymeric Aurintricarboxylic Acid, a Potent Inhibitor of Protein-Nucleic Acid Interactions; American Chemical Society; 1980.	
	42	OBERBAUMER ET AL.; Detection of RNA on Northern Blots by Negative Staining with Aurintricarboxylic Acid; Journal Biochemistry; pg. 77-79; 1990.	
	43	GIVENS ET AL.; Inhibition of RNA-directed DNA Polymerase by Aurintricarboxylic Acid; Nucleic Acids Research; vol. 3, no. 2; February 1976.	
	44	HALLICK ET AL.; Use of Aurintricarboxylic Acid as an Inhibitor of Nucleases During Nucleic Acid Isolation; Nucleic Acids Research; vol. 4, no. 9; September 1977.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	10/604,779
Filing Date	08/15/2003
First Named Inventor	Matt Ewert
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	1372.49.PRC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	45	GUO ET AL.; Aurin Tricarboxylic Acid Directly Activates Platelets; Thrombosis Research; pg. 77-88; 1993.	
	46	GONZALEZ ET AL.; Fractionation and Structural Elucidation of the Active Components of Aurintricarboxylic Acid, A Potent Inhibitor of Protein Nucleic Acid...; Biomedical Press; 1979.	
	47	BIRNBOIM, H.C.; Rapid Extraction of High Molecular Weight RNA from Cultured Cells & Granulocytes for Northern Analysis; Nucleic Acids Research; vol. 16, no. 4; 1988.	
	48	SKIDMORE ET AL.; Characterization and Use of the Potent Ribonuclease Inhibitor Aurintricarboxylic Acid for the Isolation of RNA.. Journal of Biological Chemistry; pg. 73-80; 1989.	
	49	TSUTSUI ET AL.; Fractionation of Aurintricarboxylic Acid & Effects of its Components on Nuclear Swelling & Nucleic Acid Synthesis; Biomedical Press; pg. 14-23; 1978.	
	50	NAKANE ET AL.; Differential Inhibition of Various Deoxyribonucleic Acid Polymerases by Evans Blue & Aurintricarboxylic Acid; Journal of Biological Chemistry; pg. 91-96; 1988.	
	51	ROZALSKI ET AL.; Effects of Fibrinogen Receptor Antagonist GR144053F & Aurintricarboxylic Acid on Platelet Activation and Degranulation; Biochemical Pharmacology; pg. 1399-1408; 2001.	
	52	BROWNE ET AL.; Binding Studies of Cationic Thymidyl Deoxyribonucleic Guanidine to RNA Homopolynucleotides; July 1995.	
	53	HUANG ET AL.; Electric Manipulation of Bioparticles and Macromolecules on Microfabricated Electrodes; Analytical Chemistry; vol. 73, no. 7; April 1, 2001.	
	54	CHENG ET AL.; Isolation of Cultured Cervical Carcinoma Cells Mixed with Peripheral Blood Cells on a Bioelectronic Chip; Analytical Chemistry; vol. 70, no. 11; June 1, 1998.	
	55	LI ET AL.; Transport, Manipulation, and Reaction of Biological Cells On-Chip Using Electrokinetic Effects; Analytical Chemistry; vol. 69, no. 8; April 15, 1997.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Compleat if Kn wn

Application Number	10/604,779
Filing Date	08/15/2003
First Named Inventor	Matt Ewert
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	1372.49.PRC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	56	YANG ET AL.; Granted, Stacked Microlaboratory for Biological Agent Detection with DNA & Immunoassays; BioSensors&BioElectronics; pg. 605-618; 2002.	
	57	EDMAN ET AL.; Electric Field Directed Nucleic Acid Hybridization on Microchips; Nucleic Acids Research; vol. 25, no. 24; 1997.	
	58	EWALT ET AL.; Detection of Biological Toxins on an Active Electronic Microchip; Analytical Biochemistry; pg. 162-172; 2001.	
	59	FORSTER ET AL.; A Laminated, Flex Structure for Electronic Transport & Hybridization of DNA; BioSensors & BioElectronics; pg. 187-194; 2001.	
	60	BOOM ET AL.; Rapid and Simple Method for Purification of Nucleic Acids; Journal of Clinical Microbiology; vol. 28, no. 3; pg. 495-503.	
	61	BRUISTEN ET AL.; Stability of HIV-1 RNA in Blood During Specimen Handling and Storage Prior to Amplification by NASBA-QT; Journal of Biorelogical Methods; pg. 199-207; 1997.	
	62	READ, S.J.; Recovery Efficiencies of Nucleic Acid Extraction Kits as Measured by Quantitative LightCycler PCR; Journal of Clinical Pathol; pg. 86-90; 2001.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.